Setidegrasib results published in New England Journal of Medicine FORT MYERS, Fla., April 2, 2026 /PRNewswire/ -- Results of a Phase 1 clinical study conducted with participation from Florida Cancer ...

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that may play an important role in colon cancer. Researchers also showed how this ...